| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Cheng Andrew | President and CEO, Director | C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO | /s/ Jonathan Young, Attorney-in-Fact | 2025-06-12 | 0001778307 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AKRO | Common Stock | Sale | -$798K | -14.8K | -2.5% | $53.76 | 579K | Jun 10, 2025 | Direct | F1, F2 |
| transaction | AKRO | Common Stock | Sale | -$824K | -15.2K | -2.62% | $54.35 | 564K | Jun 10, 2025 | Direct | F1, F3 |
| transaction | AKRO | Common Stock | Sale | -$423K | -7.84K | -1.39% | $53.99 | 556K | Jun 10, 2025 | Direct | F4, F5 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person. |
| F2 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.075 to $54.07, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F3 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.08 to $54.353, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F4 | Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person. |
| F5 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.128 to $54.00, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |